Acquired renal glucosuria in an undifferentiated connective tissue disease patient with a SLC5A2 heterozygous mutation

A case report

Xiangchen Gu, MD, Min Chen, MD, Yanqiu Xu, MD, Yi Wang, MD

Abstract

Introduction: Renal glucosuria is a renal tubular disorder caused by genetic conditions, drugs, and poisons. Mutations in the SLC5A2 gene are recently found to be responsible for the inherited renal glucosuria, while undifferentiated connective tissue disease (UCTD) was not considered pathogenic for renal glucosuria. Here, we present a case of acquired renal glucosuria in a UCTD patient.

Patient concerns: A 30-year-old woman was seen in the outpatient clinic for complaints of frequent urination and dysuria. Laboratory tests showed a urinary tract infection (UTI) and persistent renal glucosuria. After antibiotic treatment, the UTI symptoms were relieved, but the renal glucosuria remained.

Diagnosis: Laboratory tests ruled out renal tubular acidosis and diabetes mellitus. Genetic analysis showed a heterozygous mutations in the SLC5A2 gene. Meanwhile, immunological tests showed a high antinuclear antibody titer (1:160) and an elevated anti-Rho/SSA antibody level. Schirmer test, tear breakup time, and lip biopsy results were all negative. The patient did not meet the criteria for any known connective diseases. Therefore, she was diagnosed with UCTD. Interventions: The patient was started with the treatment of Hydroxychloroquine.

Outcomes: Hydroxychloroquine treatment resolved the renal glucosuria. The patient’s follow-up urinalysis showed no glucosuria at all.

Lessons: This is the first case report to demonstrate that UCTD may induce renal glucosuria in a patient with a heterozygous mutation in SLC5A2. This case suggests that during the process of diagnosing renal glucosuria, in addition to familial renal glucosuria (FRG), autoimmune diseases, though rare, should also be taken into consideration.

Abbreviations: CTDs = connective tissue diseases, DM/PM = dermatomyositis/polymyositis, FRG = familial renal glucosuria, HCO = hydroxychloroquine, MCTD = mixed connective tissue disease, MPGN = membranoproliferative glomerulonephritis, NCCT = Na+/Cl- co-transporter, PIG = podocyte infolding glomerulopathy, RA = rheumatoid arthritis, SGLT2 = sodium-glucose co-transporter2, SLC12A3 = solute carrier family 12 member 3, SLC5A2 = solute carrier family 5, member 2, SLE = systemic lupus erythematosus, SS = sjögren syndrome, SSC = systemic sclerosis, UCTD = undifferentiated connective tissue disease, UTI = urinary tract infection.

Keywords: renal glucosuria, SGLT2, SLC5A2, UCTD

1. Introduction

Renal glucosuria is a renal tubular disorder characterized by persistent isolated glucosuria in the absence of hyperglycemia.\(^{[1]}\)

2. Case presentation

A 30-year-old Chinese woman was referred to the renal division because of frequent urination and dysuria for almost 2 weeks. She had been healthy without any diagnosed diseases, she was not taking any medications, and her clinical examination revealed no significant findings.

The causes of renal glucosuria include a wide range of insults to proximal tubular cells, including genetic conditions, drugs, and poisons.\(^{[2]}\) Mostly, the inherited form of this disorder is called familial renal glucosuria (FRG), which is a rare renal tubular disorder due to autosomal recessive mutations in the SLC5A2 gene located on human chromosome 16p11.2.\(^{[3,4]}\) The SLC5A2 gene encodes the low-affinity sodium/glucose cotransporter SGLT2, which is responsible for most glucose reabsorption in the kidney.\(^{[5,6]}\) A previous study has suggested that overt glucosuria requires the individual to be homozygous or compound heterozygous.\(^{[7]}\)

Herein, we report an unusual case of isolated renal glucosuria in an undifferentiated connective tissue disease (UCTD) patient with a heterozygous mutation in SLC5A2.
The laboratory results showed pyuria and bacteriuria, which suggested a clinical diagnosis of urinary tract infection (UTI). The oral antibiotic levofloxacin was used to treat the UTI. After the treatment, the urinalysis was normal except for persistent glucosuria (urine glucose +2+). Other test results were as follows: fasting plasma glucose (4.74 mmol/L), hemoglobin A1C 5.1%, oral glucose tolerance test (5.4 mmol/L), urine microalbumin/creatinine (9.89 mg/g), serum potassium (4.6 mmol/L), serum sodium (139 mmol/L), chloride (97 mmol/L), and bicarbonate (23.7 mmol/L). Diabetes mellitus, renal tubular acidosis, and Fanconi syndrome were excluded. Then, FRG was taken into consideration. With the consent of the patient, genomic DNA was extracted from peripheral leukocytes. The entire coding region and adjacent intronic segments of SLC5A2 were screened for mutations by genome sequencing (Jinyu, Shanghai). The results showed that the patient had a heterozygous C to A base pair substitution at 1540 in exon 12. This mutation causes a Pro to Ser missense mutation at position 514 (Fig. 1). The heterozygous mutation has not been reported before and may not cause mild to moderate glucosuria. To rule out other possible diseases, immunological tests were performed. Surprisingly, the tests showed a high antinuclear antibody (ANA) titer (1:160), an elevated anti-Rho/SSA antibody level, a decrease in C3 and C4, and normal IgG, IgA, IgM, and RF levels. Schirmer test, tear breakup time, and lip biopsy results were all negative (Table 1). The patient did not meet the criteria for any known connective diseases. Therefore, she was diagnosed with UCTD. The patient was then treated with Plaquenil (hydroxychloroquine) 100 mg twice a day orally for 6 months. The patient’s monthly follow-up urinalysis showed weakly positive to negative glucosuria during 6 months of treatment (Table 2).

Figure 1. Genome sequencing of all exon regions of SLC5A2 (A) Schematic diagram of the SLC5A2 gene, with exons (boxes) and introns (lines). (B) Genome sequencing revealed a heterozygous mutation in C1540T which causes Pro to Ser substitution at position 1540.

| Data                  | Results          | Normal Range |
|-----------------------|------------------|--------------|
| Blood                 |                  |              |
| Fast blood glucose (mmol/L) | 4.74             | <6.11        |
| OGTT (mmol/L)         | 5.4              | <7.8         |
| Hemoglobin A1C (%)    | 5.1              | 4.5–6.3      |
| Urea nitrogen (mmol/L)| 4.2              | 2.5–6.5      |
| Creatinine (mmol/L)   | 45               | 36–125       |
| Sodium (mmol/L)       | 139              | 136–145      |
| Potassium (mmol/L)    | 4.6              | 3.5–5.3      |
| Chloride (mmol/L)     | 97.0             | 96–108       |
| pH                    | 7.35             | 7.35–7.45    |
| Bicarbonate (mmol/L)  | 23.7             | 21.4–27.3    |
| C3 (g/L)              | 0.63             | 0.79–1.52    |
| C4 (g/L)              | 0.12             | 0.16–0.38    |
| IgG (g/L)             | 10.40            | 7–16         |
| IgA (g/L)             | 2.38             | 0.7–4        |
| IgM (g/L)             | 1.47             | 0.4–2.3      |
| ACA                   | Neg              | negative     |
| Anti SSA/Ro-52        | +                | negative     |
| ANA                   | 1:160            | negative     |
| MPO-ANCA              | Neg              | negative     |
| PR3-ANCA              | Neg              | negative     |
| Anti-CCP (IU/mL)      | 0.25             | <0.95        |
| RF (IU/mL)            | <11.00           | 0–20         |
| GPI (IU/mL)           | 0.01             | <0.33        |
| Urine                 |                  |              |
| MCVD (g/mg)           | 9.89             | <20          |
| glucosuria            | 2+               | negative     |
| PH                    | 6.5              | 5.0–8.0      |
| 24h urinary protein (g/24h) | 0.13   | 0.028–0.141 |

Neg = negative.
Table 2

| Urine glucose before and with hydroxychloroquine (HCQ) treatment. |
|---------------------------------------------------------------|
| Four weeks before | Three Weeks before | Two Weeks before | One Week before | One Months (HCQ) | Two Months (HCQ) | Three Months (HCQ) | Four Months (HCQ) | Five Months (HCQ) | Six months (HCQ) |
| Urine glucose | 2+ | + | 2+ | 2+ | ± | Neg | Neg | Neg | Neg |

Neg = negative.

3. Discussion

Under normal physiological conditions, proximal tubules in the kidneys reabsorb almost 180g of glucose daily via SGLT2, a kidney-specific transporter, accounting for the reabsorption of glucose filtered by glomeruli. The protein SGLT2, encoded by SLC5A2, a 7.6kb gene containing 14 exons, has 672 amino acids, with an inferred secondary structure consisting of 14 transmembrane-spanning domains and both the NH2 and COOH termini facing the extracellular milieu.

Thus, mutations in the SLC5A2 gene are responsible for renal glucosuria. A previous study has suggested that homozygous or compound heterozygous mutations in the SLC5A2 gene can cause overt glucosuria. Other research has also indicated that the heterozygous mutation of SLC5A2 might cause “mild” glucosuria. However, increased glucose excretion was not observed in all individuals with similar or identical mutations, heterozygosity, in particular, indicating that other genetic or nongenetic factors are involved.

In this patient, nongenetic factors were also considered because she only had 1 heterozygous mutation in SLC5A2 in exon 12 and had never presented with glucosuria before. Surprisingly, the immunological tests demonstrated a high ANA titer (1:160) and positive antibodies to Rho/SSA. The serological profile in this patient was consistent with Sjogren syndrome (SS). However, she did not have any other associated symptoms suggestive of primary SS (pSS); thus, the patient was diagnosed with UCTD.

The term undifferentiated connective tissue disease (UCTD) refers to unclassifiable systemic autoimmune disorders that share clinical and serological manifestations with definite connective tissue diseases (CTDs), such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjogren syndrome (Sjogren syndrome), mixed connective tissue disease (MCTD), and rheumatoid arthritis (RA), but not fulfilling any of the existing classification criteria. This disease most commonly presents symptoms such as arthralgia, arthritis, Raynaud phenomenon, leukopenia, xeroctomia, and xerophthalmia. In some rare cases, UCTD may present as cardiac tamponade, focal cardiac arrest, membranoproliferative glomerulonephritis (MPGN), and podocyte infolding glomerulopathy (PIG), indicating that UCTD induces the autoantibody-mediated immune response, leading to different types of damage to different tissues, including tissues in the cardiovascular and renal systems.

Meanwhile, the presence of anti-SSA antibodies in both the S2 and 60kD antigens has been correlated with progression to pSS. In one UCTD patient cohort, those with anti-SSA and/or anti-SSB antibodies presented an SS-like disease. In this patient, a high ANA titer and positive antibodies to Rho/SSA indicate progression to pSS, a well-defined CTD, in the future.

Furthermore, this patient has a heterozygous mutation in SLC5A2 in exon 12. According to the postulated topology of SGLTs, it has been suggested that transmembrane domains 10 to 13 may play a pivotal role in sugar binding and translocation. Therefore, it is reasonable to assume that mutations in these domains would result in significantly impaired SGLT2 function, leading to severe glucosuria. Indeed, Santer et al reported cases presenting with extreme glucosuria (glucose excretion > 100 g/1.73 m²/day), with either homozygous or double heterozygous mutations affecting SGLT2 residues of transmembrane domains 10 to 13.

Thus, the heterozygous mutation in exon 12 could be responsible for latent SGLT2 hypofunction, and the underlying UCTD-associated autoimmunity could have induced the manifestation of its hypofunction. Therefore, the autoantibody to SGLT2 may be a nongenetic factor of the mild to moderate glucosuria in this patient with a heterozygous mutation in SLC5A2.

Interestingly, the same condition has been reported in other cases. An anti-SSA antibody-positive patient was diagnosed with acquired Gitelman syndrome with an SLC12A3 heterozygous mutation. The researcher presumed that the heterozygous mutation could be responsible for the latent hypofunction of NCCT causing acquired Gitelman syndrome. We also reported the case of a pSS patient with an SLC12A3 heterozygous mutation presenting with acquired Gitelman syndrome. Therefore, all of these case reports indicate that patients with autoimmune diseases, especially those on the spectrum of SS-like diseases, are more susceptible to renal tubular disorders, typically patients with heterozygous mutations in genes encoding renal tubular transporters.

Additionally, renal glucosuria fully recovered after the treatment of UCTD with hydroxychloroquine; this finding strongly supports the mediation of renal glucosuria by autoantibodies. Data have shown that in SLE, early intervention with hydroxychloroquine can delay or prevent the development of more severe sequelae. At the same time, it is important to follow up with this patient regularly, as her condition might eventually evolve into pSS.

This case report has some limitations. First, glucosuria was not quantitatively examined but was only qualitatively expressed as positive. Additionally, in general, renal biopsies are unnecessary for isolated renal glucosuria patients, so we did not confirm the hypothesis in this case report by a kidney biopsy. Thus, it is impossible for us to obtain histological evidence of the direct autoantibody anti-SGLT2 in proximal tubular epithelial cells. Unfortunately, we could not perform immunofluorescence or immunoblot analysis to test for the presence of autoantibodies reactive to kidney tissue or endogenous kidney protein.

To the best of our knowledge, this is the first report to demonstrate that UCTD-associated autoimmunity may induce renal glucosuria in a patient with an SLC5A2 heterozygous mutation. This case suggests that during the process of diagnosing renal glucosuria, in addition to FRG, autoimmune diseases, though rare, should also be taken into consideration.

Acknowledgments

Thank you.
Author contributions

Formal analysis: Xiangchen Gu, Yanqiu Xu.
Investigation: Xiangchen Gu, Min Chen.
Project administration: Yanqiu Xu.
Supervision: Min Chen, Yi Wang.
Writing – original draft: Xiangchen Gu.
Writing – review & editing: Yi Wang.

References

[1] Elsas LJ, Rosenberg LE. Familial renal glycosuria: a genetic reappraisal of hexose transport by kidney and intestine. J Clin Invest 1969;48:1845–54.
[2] Balak DM, Bouwes Bavinck JN, de Vries AF, et al. Drug-induced Fanconi syndrome associated with fumaric acid esters treatment for psoriasis: a case series. Clin Kidney J 2016;9:82–9.
[3] Wells RG, Mohandas TK, Hediger MA. Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere. Genomics 1993;17:787–9.
[4] Wells RG, Pajor AM, Kanai Y, et al. Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Physiol 1992;263:F459–65.
[5] Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994;93:397–404.
[6] Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10–8.
[7] Santner R, Kimmer M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873–82.
[8] Marusic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009;53:873–83.
[9] Turk E, Wright EM. Membrane topology motifs in the SGLT cotransporter family. J Membr Biol 1997;159:1–20.
[10] Yu L, Xu Q, Hou P, et al. Decreased expression and function of sodium glucose co-transporter 2 from a novel C-terminal mutation: a case report. BMC Nephrol 2016;17:31–4.
[11] Santner R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 2010;5:133–41.
[12] Mosca M, Tani C, Carli L, et al. Undifferentiated CTD: a wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol 2012;26:73–7.
[13] Mosca M, Tani C, Vagnani S, et al. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun 2014;48–49:50–2.
[14] Mosca M, Tani C, Neri C, et al. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 2006;6:1–4.
[15] Hari P, Kondu A, Manickam P, et al. An unusual case of undifferentiated connective tissue disease presenting as cardiac tamponade. Rheumatol Int 2012;32:231–4.
[16] Adami M, Nardin M, Morello E, et al. Fatal cardiac arrest in an adult patient with euthyroid anti-SSA/Ro-positive connective tissue disease: a case report. Int Arch Med 2009;2:15–8.
[17] Zand L, Fervenza FC, Nazer SH, et al. Membranoproliferative glomerulonephritis associated with autoimmune diseases. J Nephrol 2014;27:165–71.
[18] Matthai SM, Mohapatra A, Mathew AJ, et al. Podocyte infolding glomerulopathy (PIG) in a patient with undifferentiated connective tissue disease: a case report. Am J Kidney Dis 2018;72:149–53.
[19] Cavazzana I, Franceschini F, Belfiore N, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol 2001;19:403–9.
[20] Ceribelli A, Cavazzana I, Franceschini F, et al. Isotype switching and titer variation of anti-Ro/SSA antibodies over time in 100 patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol 2008;26:117–20.
[21] Panayotova-Heiermann M, Loo DD, Kong CT, et al. Sugar binding to Na+/glucose cotransporters is determined by the carboxyl-terminal half of the protein. J Biol Chem 1996;271:10029–34.
[22] Kusuda T, Hosoya T, Mori T, et al. Acquired gitelman syndrome in an anti-SS-A antibody-positive patient with a SLC12A3 heterozygous mutation. Intern Med 2016;55:3201–4.
[23] Gu X, Su Z, Chen M, et al. Acquired Gitelman syndrome in a primary Sjogren syndrome patient with a SLC12A3 heterozygous mutation: a case report and literature review. Nephrology (Carlton) 2017;22:632–5.
[24] Vaz CC, Couto M, Medeiros D, et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol 2009;28:915–21.